Sobi names successor to retiring CFO

26 February 2018
henrik_stenqvist_large

Experienced deal-maker Henrik Stenqvist (pictured above) will take over from retiring Mats-Olof Wallin to become the chief financial officer (CFO) of rare diseases specialist Swedish Orphan Biovitrum (STO: SOBI), the company has announced.

Mr Stenqvist will join the Stockholm-based firm in late spring, becoming a member of its executive committee.

He is currently CFO of Swedish contract development and manufacturing organization Recipharm (STO: RECI) and in total has some 25 years of experience of finance and management positions in pharma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology